Journal of gastroenterology and hepatology · 2015
Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Honda Yohji, Takahashi Shoichi, Zhang Yizhou, Ono Atsushi, Murakami Eisuke, Shi Niu, Kawaoka Tomokazu, Miki Daiki, Tsuge Masataka, Hiraga Nobuhiko, Abe Hiromi, Ochi Hidenori, Imamura Michio, Aikata Hiroshi, Chayama Kazuaki
Аннотация
BACKGROUND AND AIM: Zoledronic acid (ZOL) is a nitrogen-containing bisphosphonate and is used to reduce cancer-induced osteolysis. We reported previously that ZOL delayed both the growth and pain progression of bone metastases from hepatocellular carcinoma. The present study was designed to evaluate the effects of ZOL on hepatoma cell lines and the molecular mechanisms of such effects.
METHODS: Cell viability assay, scratch assay, immunohistochemistry, Western blotting, and flow cytometry analysis were performed using Huh7 and HepG2 cells treated with and without ZOL.
RESULTS: ZOL reduced cell growth in a dose-dependent manner and prevented cell migration when used at a concentration exceeding 10 μM. Immunohistochemistry showed that the inhibitory effects of ZOL on hepatoma cell progression was not due to the suppression of Ras and RhoA expression but due to inhibition of their translocation from the cytosol to the cell membrane, which terminates mevalonate pathway. Immunoblotting and flow cytometry showed that ZOL inhibited the mitogen-activated protein kinase pathway (MAPK) and induced apoptosis of hepatoma cells.
CONCLUSIONS: Our results indicated that ZOL prevented cell growth and metastasis based on direct antitumor effects in hepatoma cells. The use of ZOL could not only suppress the progression to bone metastatic lesions but also prevented growth of primary hepatocellular carcinoma.
METHODS: Cell viability assay, scratch assay, immunohistochemistry, Western blotting, and flow cytometry analysis were performed using Huh7 and HepG2 cells treated with and without ZOL.
RESULTS: ZOL reduced cell growth in a dose-dependent manner and prevented cell migration when used at a concentration exceeding 10 μM. Immunohistochemistry showed that the inhibitory effects of ZOL on hepatoma cell progression was not due to the suppression of Ras and RhoA expression but due to inhibition of their translocation from the cytosol to the cell membrane, which terminates mevalonate pathway. Immunoblotting and flow cytometry showed that ZOL inhibited the mitogen-activated protein kinase pathway (MAPK) and induced apoptosis of hepatoma cells.
CONCLUSIONS: Our results indicated that ZOL prevented cell growth and metastasis based on direct antitumor effects in hepatoma cells. The use of ZOL could not only suppress the progression to bone metastatic lesions but also prevented growth of primary hepatocellular carcinoma.
Предметные рубрики MeSH
ApoptosisBone NeoplasmsCarcinoma, HepatocellularCell Growth ProcessesCell Line, TumorCell MembraneCell MovementCell SurvivalCytosolDepression, ChemicalDiphosphonatesDose-Response Relationship, DrugHep G2 CellsHumansImidazolesLiver NeoplasmsMevalonic AcidMitogen-Activated Protein KinasesSignal TransductionZoledronic Acid